Although gout predominantly occurs in men, a Global Burden of Disease Study analysis revealed a rise in gout burden worldwide, especially among women [3]. Therefore, studying this condition in women has become increasingly important.
Dr Chio Yokose (Massachusetts General Hospital, USA) presented the results of 2 separate analyses from 2 prospective general health cohort studies: Nurses’ Health Study (NHS; n=18,247 women; 1984–2018) and the Health Professionals Follow-Up Study (HPFS; n=10,899 men; 1986–2018).
In the NHS, 530 incident gout cases were discovered; 983 cases were observed in the HPFS. Genetic risk scores (GRS) were calculated based on 114 urate SNPs from European ancestry meta-analyses. Biennial health questionnaires including incident gout, BMI, and data on exposure to the DASH diet (considered healthy) and western diet (considered unhealthy) were collected. The first analysis assessed the potential interaction effect between genetic predisposition and diet on incident gout in US women, based on data from the NHS [1]. Cox proportional hazards model was used to analyse the association between genetics, diet, and the risk of incident gout. Based on GRS scores, participants were divided into 2 groups: those with an elevated genetic risk of gout (GRS above the mean) and those with a low genetic risk of gout (GRS below the mean). Diet adherence was categorised in quintiles. Three BMI groups were computed: normal weight (BMI <25), overweight (BMI 25–29.9), and obese (BMI ≥30). The model was adjusted for known risk factors of gout, such as age, BMI, red meat consumption, and the use of diuretics.
The risk of gout increased in women who adhered less to the DASH diet, especially in genetically predisposed women. The relative risk of women with high GRS increased from 1.76 (best adherence to DASH diet) to 2.79 (worst adherence to DASH diet; see Figure). In women with low GRS, the relative risk increased from 1 (best adherence to DASH diet) to 1.43 (worst adherence to DASH diet). Subsequent interaction analysis trended towards significance, with a relative excess risk due to interaction (RERI) of 0.57 (P=0.06). No genetics-diet interaction effect on incident gout was observed for the western diet (RERI 0.20; P=0.52).
Figure: Joint impact of DASH diet and GRS on the relative risk of incident gout in women [1]
GRS, genetic risk score; DASH, Dietary Approaches to Stop Hypertension; Q, quintile of diet adherence: Q1 is lowest adherence, Q5 is highest adherence.
The second analysis was based on both cohorts and examined to what extent excess weight and genetic predisposition for gout interact on the risk of incident gout. Although excess weight is an established risk factor for gout, weight-gene interaction effects have not yet been analysed in prior gout studies.
Results demonstrated that excessive weight in men was related to an increased risk of incident gout. Analysis of the GRS showed that this effect was amplified in genetically predisposed men. Relative excess risk for excess weight (overweight or obese) compared with normal weight trended towards significance (P=0.08). The investigated interaction effect was more profound among women with excess weight. Additive interaction analysis confirmed this; incident gout was higher in overweight and obese women with a high genetic risk compared with overweight and obese women with a low genetic risk (RERI 1.69; P<0.01).
Dr Yokose argued that the results of these 2 prospective cohort studies suggest that dietary interventions and lifestyle interventions targeting weight can significantly reduce the number of gout cases. Women who have a genetic predisposition for gout could particularly benefit from this. However, further work is needed before a GRS could be applied to gout prediction.
- Yokose C, et al. Gene-Diet Interaction on the Risk of Incident Gout Among Women: Prospective Cohort Study over 34 Years. OP0203, EULAR 2021 Virtual Congress, 2–5 June.
- Yokose C, et al. Does Excess Weight Affect Gout Risk Differently Among Genetically Predisposed Individuals? Sex-Specific Prospective Cohort Findings over > 32 Years. OP0202, EULAR 2021 Virtual Congress, 2–5 June.
- Safiri S, et al. Arthritis Rheumatol. 2020; 72(11):1916-27.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« SELECT-AXIS: 64-week results of upadacitinib in active ankylosing spondylitis Next Article
Fluoxetine doesn’t reduce depression during stroke recovery »
« SELECT-AXIS: 64-week results of upadacitinib in active ankylosing spondylitis Next Article
Fluoxetine doesn’t reduce depression during stroke recovery »
Table of Contents: EULAR 2021
Featured articles
COVID-19 Update
Rituximab or JAK inhibitors increase the risk of severe COVID-19
Updates on COVID-19 vaccines in patients with rheumatic disease
Immunomodulatory therapies for severe COVID-19: literature update
New Developments in Rheumatoid Arthritis
JAK inhibitors and bDMARDs not associated with increased risk of serious infections in RA
Remote management of RA is a feasible alternative for outpatient follow-up
TOVERA: Ultrasound is a promising biomarker of early treatment response
The risks of polypharmacy in RA
ABBV-3373: A potential new therapeutic agent for RA
JAK inhibitors and bDMARDs show comparable effectiveness
Spondyloarthritis: Progression in Therapies
SELECT-AXIS: 64-week results of upadacitinib in active ankylosing spondylitis
Guselkumab efficacious in PsA patients with inadequate response to TNF inhibition
Faecal microbiota transplantation not effective in active peripheral PsA
Risankizumab meets primary and ranked secondary endpoints in PsA
Prognostic factors for minimal disease activity in early psoriatic arthritis revealed
Imaging in Large-Vessel Vasculitis
PET/CT is a reliable measure of disease activity in LVV, but does not predict future relapses
Ultrasound is useful for disease monitoring in giant cell arteritis
Prevention in Rheumatic Diseases
Air pollution predicts decreased response to biological treatment in rheumatic diseases
Passive smoking associated with an increased risk of RA
Gene-Environment Interaction in Gout
Gene-diet and gene-weight interactions associated with the risk of gout
What Is New in Systemic Lupus Erythematosus
Intensified treatment regimen of anifrolumab for lupus nephritis is promising
Systemic lupus erythematosus: increased risk of severe infection
Juvenile Idiopathic Arthritis and Osteoarthritis
Efficacy and safety of secukinumab in juvenile idiopathic arthritis
Emerging therapies and future treatment directions in osteoarthritis
Related Articles
November 21, 2024
XG005 relieves OA symptoms in phase 2b study
July 21, 2022
OA associated with alcohol and drug abuse
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com